S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
Positive News Sentiment  
NASDAQ:PBYI

Puma Biotechnology - PBYI Stock Forecast, Price & News

$4.24
-0.18 (-4.07%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.22
▼
$4.51
50-Day Range
$3.98
▼
$5.08
52-Week Range
$1.60
▼
$5.16
Volume
234,692 shs
Average Volume
302,040 shs
Market Capitalization
$193.51 million
P/E Ratio
19.27
Dividend Yield
N/A
Price Target
$8.00

Puma Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
88.7% Upside
$8.00 Price Target
Short Interest
Healthy
2.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.66mentions of Puma Biotechnology in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$176,342 Sold Last Quarter
Proj. Earnings Growth
-57.89%
From $0.19 to $0.08 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

124th out of 1,054 stocks

Pharmaceutical Preparations Industry

49th out of 517 stocks

See Top Rated MarketRank™ Stocks Here

PBYI stock logo

About Puma Biotechnology (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Stock News Headlines

January 25, 2023 | finance.yahoo.com
Puma Biotechnology's (NASDAQ:PBYI) investors will be pleased with their decent 96% return over the last year
January 12, 2023 | finance.yahoo.com
Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
January 29, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 12, 2023 | reuters.com
PBYI.OQ - | Stock Price & Latest News | Reuters
January 9, 2023 | finance.yahoo.com
Puma Biotechnology, Inc. (PBYI)
December 20, 2022 | finance.yahoo.com
Institutional investors own a significant stake of 45% in Puma Biotechnology, Inc. (NASDAQ:PBYI)
December 15, 2022 | finance.yahoo.com
Why Shares of Puma Biotechnology Rose This Week
December 1, 2022 | finance.yahoo.com
15 Best Affordable Stocks Under $30
January 29, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 22, 2022 | finance.yahoo.com
Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?
November 14, 2022 | finance.yahoo.com
Why Puma Biotech (PBYI) is a Top Momentum Stock for the Long-Term
November 11, 2022 | ca.finance.yahoo.com
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
November 9, 2022 | benzinga.com
Short Volatility Alert: Puma Biotechnology, Inc.
November 9, 2022 | finance.yahoo.com
Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion
November 9, 2022 | finance.yahoo.com
Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations
November 8, 2022 | finance.yahoo.com
Why Puma Biotechnology, Inc. (NASDAQ:PBYI) Looks Like A Quality Company
November 4, 2022 | apnews.com
Puma Biotechnology Reports Third Quarter 2022 Financial Results
November 4, 2022 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Puma Biotechnology (PBYI)
November 4, 2022 | finance.yahoo.com
Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss
November 4, 2022 | finance.yahoo.com
Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates
October 27, 2022 | finance.yahoo.com
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
September 20, 2022 | finance.yahoo.com
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
September 11, 2022 | finance.yahoo.com
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
August 24, 2022 | nasdaq.com
With 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big guns
August 12, 2022 | finance.yahoo.com
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Profit Outlook
August 8, 2022 | finance.yahoo.com
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
August 4, 2022 | finance.yahoo.com
Puma Biotechnology Reports Second Quarter 2022 Financial Results
See More Headlines
Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Company Calendar

Last Earnings
11/03/2022
Today
1/29/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PBYI
CUSIP
N/A
CIK
1401667
Web
www.pumabiotechnology.com
Phone
(424) 248-6500
Fax
424-248-6501
Employees
196
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+88.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.22
Trailing P/E Ratio
19.27
Forward P/E Ratio
22.32
P/E Growth
1.86
Net Income
$-29,130,000.00
Net Margins
4.50%
Pretax Margin
4.64%
Return on Equity
84.14%
Return on Assets
4.78%

Debt

Debt-to-Equity Ratio
4.42
Current Ratio
2.04
Quick Ratio
1.95

Sales & Book Value

Annual Sales
$253.20 million
Price / Sales
0.76
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.06) per share
Price / Book
-70.67

Miscellaneous

Outstanding Shares
45,640,000
Free Float
35,964,000
Market Cap
$193.51 million
Optionable
Optionable
Beta
0.92

Key Executives

  • Mr. Alan H. AuerbachMr. Alan H. Auerbach (Age 53)
    Founder, Chairman, Pres, CEO & Sec.
    Comp: $1.11M
  • Mr. Maximo F. NouguesMr. Maximo F. Nougues (Age 54)
    CFO & Principal Accounting Officer
    Comp: $627.85k
  • Dr. Alvin F. Wong Pharm.d.
    Chief Scientific Officer
  • Mr. Douglas Hunt B.Sc. (Age 58)
    FRAPS, Sr. VP of Regulatory Affairs, Medical Writing & Project Management
    Comp: $509.04k
  • Mr. Jeffrey Jerome Ludwig (Age 57)
    Chief Commercial Officer
    Comp: $735.01k
  • Mr. Mariann Ohanesian
    Sr. Director of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PBYI Stock - Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings or view top-rated stocks.

What is Puma Biotechnology's stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month target prices for Puma Biotechnology's stock. Their PBYI share price forecasts range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 88.7% from the stock's current price.
View analysts price targets for PBYI or view top-rated stocks among Wall Street analysts.

How have PBYI shares performed in 2023?

Puma Biotechnology's stock was trading at $4.23 on January 1st, 2023. Since then, PBYI stock has increased by 0.2% and is now trading at $4.24.
View the best growth stocks for 2023 here.

When is Puma Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our PBYI earnings forecast.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) released its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.10. The biopharmaceutical company had revenue of $57.10 million for the quarter, compared to analyst estimates of $51.40 million. Puma Biotechnology had a trailing twelve-month return on equity of 84.14% and a net margin of 4.50%.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.84%) and Patriot Financial Group Insurance Agency LLC (0.06%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Michael Patrick Miller, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends.

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $4.24.

How much money does Puma Biotechnology make?

Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $193.51 million and generates $253.20 million in revenue each year. The biopharmaceutical company earns $-29,130,000.00 in net income (profit) each year or $0.22 on an earnings per share basis.

How many employees does Puma Biotechnology have?

The company employs 196 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501.

This page (NASDAQ:PBYI) was last updated on 1/29/2023 by MarketBeat.com Staff